Moderna Therapeutics, a biotech company valued at more than $7 billion, is plotting to raise $500 million in what would be the sector’s largest-ever initial public offering.
The company, based in Cambridge, Mass., filed with the Securities and Exchange Commission on Friday in the first step toward listing its shares on the Nasdaq.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
As expected, Moderna stock falls from its IPO price on the first day of trading. https://news.alphastreet.com/moderna-nasdaq-mrna-stock-raises-over-600-million-through-ipo-to-debut-on-friday/
These guys are quacks. Savy, senior executives won’t leave a company with truly innovative products that truly work. They will leave, however, if products are phony and full of hype. I have not seen anything announced by Moderna so far, that indicate therapies that actually work. Invest in these guys at your own peril.